203 related articles for article (PubMed ID: 33000263)
1. Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4.
Bi R; Deng Y; Tang C; Xuan L; Xu B; Du Y; Wang C; Wei W
Oncol Rep; 2020 Nov; 44(5):1939-1948. PubMed ID: 33000263
[TBL] [Abstract][Full Text] [Related]
2. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
[TBL] [Abstract][Full Text] [Related]
3. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
4. Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation.
Zhou J; Lu GD; Ong CS; Ong CN; Shen HM
Mol Cancer Ther; 2008 Jul; 7(7):2170-80. PubMed ID: 18645026
[TBL] [Abstract][Full Text] [Related]
5. Andrographolide Enhances TRAIL-Induced Apoptosis via
Deng Y; Bi R; Guo H; Yang J; Du Y; Wang C; Wei W
Int J Biol Sci; 2019; 15(3):688-700. PubMed ID: 30745855
[TBL] [Abstract][Full Text] [Related]
6. FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells.
Woo SM; Seo BR; Min KJ; Kwon TK
Oncotarget; 2015 May; 6(13):11614-26. PubMed ID: 25843953
[TBL] [Abstract][Full Text] [Related]
7. Sensitizing TRAIL‑resistant A549 lung cancer cells and enhancing TRAIL‑induced apoptosis with the antidepressant amitriptyline.
Zinnah KMA; Park SY
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080659
[TBL] [Abstract][Full Text] [Related]
8. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis.
Wei RJ; Zhang XS; He DL
Asian J Androl; 2018; 20(2):200-204. PubMed ID: 28869219
[TBL] [Abstract][Full Text] [Related]
9. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
10. Icariin sensitizes human colon cancer cells to TRAIL‑induced apoptosis via ERK‑mediated upregulation of death receptors.
Kim B; Seo JH; Lee KY; Park B
Int J Oncol; 2020 Mar; 56(3):821-834. PubMed ID: 32124960
[TBL] [Abstract][Full Text] [Related]
11. Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells.
Jung KJ; Min KJ; Bae JH; Kwon TK
Oncotarget; 2015 Jan; 6(3):1556-68. PubMed ID: 25596735
[TBL] [Abstract][Full Text] [Related]
12. 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5.
Chen Y; Wei L; Zhang X; Liu X; Chen Y; Zhang S; Zhou L; Li Q; Pan Q; Zhao S; Liu H
Oncol Rep; 2018 Nov; 40(5):2435-2444. PubMed ID: 30132536
[TBL] [Abstract][Full Text] [Related]
13. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
14. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.
Moon DO; Kim MO; Choi YH; Kim GY
Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
[TBL] [Abstract][Full Text] [Related]
16. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of TRAIL‑induced cell death by nonsteroidal anti‑inflammatory drug in human hepatocellular carcinoma cells through the ER stress‑dependent autophagy pathway.
Lee SH; Moon HJ; Lee YS; Kang CD; Kim SH
Oncol Rep; 2020 Sep; 44(3):1136-1148. PubMed ID: 32705218
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
20. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
